AGL 36.58 Decreased By ▼ -1.42 (-3.74%)
AIRLINK 215.74 Increased By ▲ 1.83 (0.86%)
BOP 9.48 Increased By ▲ 0.06 (0.64%)
CNERGY 6.52 Increased By ▲ 0.23 (3.66%)
DCL 8.61 Decreased By ▼ -0.16 (-1.82%)
DFML 41.04 Decreased By ▼ -1.17 (-2.77%)
DGKC 98.98 Increased By ▲ 4.86 (5.16%)
FCCL 36.34 Increased By ▲ 1.15 (3.27%)
FFBL 88.94 No Change ▼ 0.00 (0%)
FFL 17.08 Increased By ▲ 0.69 (4.21%)
HUBC 126.34 Decreased By ▼ -0.56 (-0.44%)
HUMNL 13.44 Increased By ▲ 0.07 (0.52%)
KEL 5.23 Decreased By ▼ -0.08 (-1.51%)
KOSM 6.83 Decreased By ▼ -0.11 (-1.59%)
MLCF 44.10 Increased By ▲ 1.12 (2.61%)
NBP 59.69 Increased By ▲ 0.84 (1.43%)
OGDC 221.10 Increased By ▲ 1.68 (0.77%)
PAEL 40.53 Increased By ▲ 1.37 (3.5%)
PIBTL 8.08 Decreased By ▼ -0.10 (-1.22%)
PPL 191.53 Decreased By ▼ -0.13 (-0.07%)
PRL 38.55 Increased By ▲ 0.63 (1.66%)
PTC 27.00 Increased By ▲ 0.66 (2.51%)
SEARL 104.33 Increased By ▲ 0.33 (0.32%)
TELE 8.63 Increased By ▲ 0.24 (2.86%)
TOMCL 34.96 Increased By ▲ 0.21 (0.6%)
TPLP 13.70 Increased By ▲ 0.82 (6.37%)
TREET 24.89 Decreased By ▼ -0.45 (-1.78%)
TRG 73.55 Increased By ▲ 3.10 (4.4%)
UNITY 33.27 Decreased By ▼ -0.12 (-0.36%)
WTL 1.71 Decreased By ▼ -0.01 (-0.58%)
BR100 11,987 Increased By 93.1 (0.78%)
BR30 37,178 Increased By 323.2 (0.88%)
KSE100 111,351 Increased By 927.9 (0.84%)
KSE30 35,039 Increased By 261 (0.75%)

ZURICH: Roche is launching a new genomic profiling kit that lets cancer researchers explore tumours without having to send tissue samples to centralised laboratories, the Swiss drugmaker said on Monday.

The AVENIO Tumour Tissue Comprehensive Genomic Profiling (CGP) Kit was developed with Roche unit Foundation Medicine, a molecular information specialist whose products help doctors match patients to appropriate therapies and clinical trials.

"The Kit complements the current CGP portfolio offered by Roche and Foundation Medicine and allows laboratories to expand their oncology research in-house," Roche said in a statement, giving no financial information about the product.

"Ultimately, a future version of the kit may lead to additional resources for clinicians to use in the diagnosis and treatment of cancer."

Comments

Comments are closed.